Trial design
Eligible COVID-19 patients who were hospitalized at Masih Daneshvari Hospital in Tehran, Iran were enrolled in this randomized, hospital-based, parallel-group, placebo-controlled trial to evaluate the effects of the combination of BCc1 and Hep-S nanomedicines on moderate COVID-19 patients.